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Abstract 
The biomedical application of discrete supramolecular metal-based structures, including 
supramolecular coordination complexes (SCCs), is still an emergent field of study. However, 
pioneering studies over the last 10 years demonstrated the potential of these supramolecular 
compounds as novel anticancer drugs, endowed with different mechanisms of action compared to 
classical small-molecules, often related to their peculiar molecular recognition properties. In 
addition, the robustness and modular composition of supramolecular metal-based structures allows 
for an incorporation of different functionalities in the same system to enable imaging in cells via 
different modalities, but also active tumor targeting and stimuli-responsiveness. Although most of 
the studies reported so far exploit these systems for therapy, supramolecular metal-based 
structures may also constitute ideal scaffolds to develop multimodal theranostic agents. Of note, the 
host-guest chemistry of 3D self-assembled supramolecular structures – within the metallacages 
family - can also be exploited to design novel drug delivery systems for anticancer 
chemotherapeutics. In this review, we aim at summarizing the pivotal concepts in this fascinating 
research area, starting with the main design principles and illustrating representative examples while 
providing a critical discussion of the state-of-the-art. A section is also included on supramolecular 
organometallic complexes (SOCs) whereby the (organic) linker is forming the organometallic bond 
to the metal node, whose biological applications are still to be explored. Certainly, the myriad of 
possible supramolecular metal-based structures and their almost limitless modularity and tunability 
suggests that the biomedical applications of such complex chemical entities will continue along this 
already promising path. 
Key words: supramolecular metal-based complexes – metallacages – cancer – drug delivery – theranostics. 
1. Introduction 
Inspired by the integrative self-sorting observed 
in nature, a variety of artificial metal-based 
supramolecular architectures have been developed in 
the last decades. Hereby, additionally to the regulated 
and controlled assembly of multi-component (bio) 
molecules, the metal-containing systems can be 
designed to include further functionalities in a very 
diverse way. Most of these supramolecular scaffolds 
consist of metal ions (Lewis acids) and multidentate 
ligands (Lewis bases) comprising heteroatoms, i.e. 
such assemblies are based on “classical” also called 
“Werner-type” coordination chemistry. Both the 
coordination geometry of the metal ions or clusters 
(nodes), as well as the geometry of the multidentate 
organic ligands (linkers), determine the structure of 
the resulting materials. If the geometrical combination 
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leads to a divergent arrangement, infinite 
coordination polymers or networks can be formed. A 
very prominent subgroup of these materials are the 
porous coordination networks – also called 
metal-organic frameworks (MOFs) – which have been 
designed for a multitude of different applications 
(Figure 1) [1, 2]. 
In contrast, if the geometrical combination 
allows for a convergent arrangement of nodes and 
linkers, discrete two- or three-dimensional structures 
– so called supramolecular coordination complexes 
(SCCs) – can be obtained (Figure 1) [3]. By fine tuning 
the employed components, i.e. judicious choice of 
metal centers and complementary multidentate 
ligands, their size and (outer and inner) shape can be 
carefully controlled [4-7], which enables the synthesis 
of compound libraries. The two commonly applied 
synthetic strategies to obtain SCCs are the so-called 
edge- and face-directed approaches [5]. The latter was 
developed by Fujita in the late 90s and is also referred 
to as the ‘paneling method’ [8]. Hereby, the SCC is 
built up using planar multidentate ligand molecules, 
which upon coordination to (convergently oriented) 
vacant sites at metal nodes, form the faces of 
supramolecular polyhedra or polygons. The edge- 
directed approaches, pioneered by Stang et al. [4, 9], 
mainly employ bidendate ‘banana-shaped’ 
pyridyl-based ligands to form the edges of SCCs, 
mostly in combination with Pd(II) and Pt(II) metal 
nodes [7]. Raymond et al. significantly progressed 
both approaches, extending the investigations 
towards the dynamic behavior [10] and chirality[11] 
of SCCs, and catalysis in SCCs [12, 13]. Nitschke et al 
introduced the concept of ‘subcomponent self- 
assembly’[14] according to which the actual linker is 
formed in situ (e.g. by imine formation out of 
aldehydes and amines) and which also allows for 
covalent post-assembly modifications of the SCCs 
[15]. Recently, Fujita and coworkers reported the 
synthesis and characterization of ‘Pd48L96’, the largest 
discrete self-assembled edge-directed polyhedron 
obtained so far, demonstrating the scalability of the 
size of SCCs [16].  
Although a variety of structures have been 
reported in the literature, SCCs have been exploited 
for diverse applications only in recent years. In fact, 
among the most attractive areas of applicability, 
catalysis [17], sensing and molecular recognition 
[18-20] are certainly the most explored. Interestingly, 
the three-dimensional SCCs as the metallacages and 
chiral helicates have received great attention in the 
biomedical context. In general, metallacages feature 
an internal cavity (as a class of metallocavitands[21]) 
accessible to guest encapsulation, and thus, 
exploitable for various functions and applications 
involving host-guest chemistry [12, 20, 22]. Instead, 
helicates have been studied for their molecular 
recognition properties of nucleic acid structures, with 
possible applications in therapy [23]. 
Moreover, a recent area of considerable interest 
is the design and development of photoactive cages 
and capsules in which either the metal ion 
complexation or the bridging ligand are endowed 
with luminescence properties [24]. Such cages provide 
both a high concentration of chromophores and 
defined cavities to govern the host–guest 
optoelectronic interactions, and can be exploited for 
the design of novel imaging agents, as well as for 
sensing and photoactivation in biological systems.
 
 
Figure 1. Different types of metal-based assemblies (examples): Coordination polymers and networks formed by divergent (left) and discreet supramolecular 
complexes formed by convergent combinations of metal nodes and organic linkers (right).  
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Figure 2. Classification of supramolecular organometallic assemblies into different groups: (A) Assemblies with organometallic nodes (i.e. carbon metal bond within 
metal node) [25-29]. (B) Assemblies with organometallic linker molecules (i.e. carbon metal bond within linker molecule) [30, 31]. (C) Supramolecular 
Organometallic Complexes (SOCs, i.e. assemblies with a carbon metal bond between node and linker) [4, 32, 33]. Green: location of organometallic bond. 
 
In addition to the SCCs built up of metal nodes 
and organic linkers by classic coordination chemistry 
using heteroatom donors, organometallic fragments 
featuring metal-carbon bonds have been introduced. 
Hereby, a carbon donor can in principle be 
implemented both in the linker molecules as well as 
in the capping ligands of the metal nodes (Figure 2). 
Concerning “organometallic nodes”, often very stable 
η5-(cyclopentadienyl) or η6-coordinated (benzene) 
metal half-sandwich or metal carbonyl complexes are 
employed (Figure 2A). In this case, the ligand is 
influencing the coordination geometry of the metal 
node, e.g. only allowing for a cis-coordination of 
potential linker molecules and therefore, determining 
the directionality leading to an edge-directed SCC 
assembly. Since the organometallic metal-ligand 
fragment is contained in the node, the assembly itself 
is still based on classic coordination chemistry. 
Examples of these compounds have been reported by 
various groups.[25-29] 
There are two options for the implementation of 
the organometallic character into the linker molecules. 
First, if the carbon donor is not interacting with the 
metal nodes of the assembly but the organometallic 
bond is an integral part of the ligand molecule itself - 
rendering it an “organometallic linker” (Figure 2B) - 
the organometallic bond-formation is primarily 
influencing the linker stability, geometry and 
properties. Therefore, the organometallic bond is only 
indirectly affecting the self-assembly, which is again 
determined by classic coordination chemistry. In this 
case, the final compound can be also classified as a 
SCC. Examples of these kind of ligands used in SCCs 
are metallocene-based linkers, featuring more than 
one heteroatom as donor, e.g. ditopic ferrocenyl- 
dicarboxylic acids [31], tetratopic pyridyl-substituted 
Fe-metallocenes [34], or ditopic linkers featuring 
N-heterocyclic carbene (NHC) complexes [30]. 
Second, if the carbon donor is part of the 
linker-node connection, the (organic) linker is forming 
the organometallic bond to the metal node, thus, 
producing supramolecular organometallic complexes 
(SOCs) (Figure 2C). In contrast to the organometallic 
metal nodes, in this case, the carbon-metal bond is 
now structurally decisive for the “organometallic 
assembly” of the resulting SOC. Multidentate linkers 
used to build up such assemblies are mainly based on 
alkynyl, metal-arene [4], or NHC-donor groups. In 
particular, multidentate NHC ligands have 
undergone an enormous development in the past 
years, pioneered by the groups of Bielawski [35], Peris 
[36], and Hahn [37], also towards implementation in 
SOCs [32, 33]. The possibility of tailoring the 
electronic and steric properties of the NHCs by 
synthetic modification of the heterocycle (e.g. so 
called backbone- or wingtip-modification) [38-41] also 
allows for the introduction of water-solubility [42] 
and therefore, renders these donors an excellent class 
for SOC linker design.  
Furthermore (late transition metal) NHC 
complexes in general are very stable and – with few 
exceptions (e.g. Ag(I) complexes) – the ligands can be 
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regarded as “spectator ligands” [43], i.e. they stick to 
the metal ion and do not dissociate or get transferred. 
As a result, there is a significant difference with 
respect to the SCCs based on classic coordination 
chemistry. The latter can be regarded as dynamic 
assemblies which in principle can reversibly form and 
disrupt. In contrast, late transition metal NHC-based 
SOCs in general can be regarded as ‘static’ structures, 
which do not reversibly assemble and disassemble. 
The strong metal-NHC bond (e.g. Au(I)-NHC bond) 
[44] disfavors a dissociation, which would lead to free 
N-heterocyclic carbene ligands. Free NHCs are 
furthermore very basic and therefore, likely to be 
protonated to form the corresponding azolium salt 
(especially under physiological conditions), which 
means they would be irreversibly removed from the 
dissociation equilibrium. This was deliberately used 
in the case of the pillarplexes, a family of NHC-based 
organometallic cavitands (a subclass of SOCs) 
featuring a tubular pore introduced in 2016 [45]. 
Interestingly, the pore can be used to selectively 
incorporate linear molecules, the pillarplexes can be 
easily made water soluble by simple anion exchange 
and the Au(I) congeners exhibit an intrinsic 
luminescence, without the necessity of further 
functionalization. Upon lowering of the pH value, the 
metal ions (in this case Ag(I)) can be released and the 
corresponding imidazolium ions are obtained, which 
was implemented in a mechanically interlocked 
molecular switch with two discreet states [46]. It is 
worth mentioning that coinage metal NHC complexes 
themselves are potentially interesting in the 
biomedical context. Hereby, silver NHC compounds 
are known to possess anti-microbial activity [47] and 
gold NHC compounds have relevance as anti-cancer 
metallodrugs [48-50]. Therefore, NHC-based SOCs 
are promising candidates for investigation towards 
biomedical applications, which was also shown in a 
very recent study on the toxicity of the pillarplexes 
[51].  
Overall, this review is not intended to present 
details on the synthetic strategies to achieve various 
SCCs or SOCs, rather to summarize some general 
design principles focusing on the most recent 
examples from those systems having applications in 
anticancer therapy. Recent thematic reviews from 
different groups have commented the exponential 
progresses made in the design, synthesis and 
numerous applications of these discrete 
nanostructures [5, 6, 17, 20, 21, 52], and we refer the 
reader to these papers for further information. Here, 
we will focus on discussing SCCs as cytotoxic agents 
or as drug delivery systems for chemotherapics, 
emphasizing the high versatility and tunability of 
these scaffolds. In addition, we will present the few 
relevant in vivo studies on anticancer SCCs, which 
validate the concept and pave the way to their clinical 
application. Thus, we aim at providing the future 
outlook for this exciting research area, which, in 
defining the various challenges, will hopefully 
stimulate new ideas within the supramolecular, 
bioinorganic and medicinal chemistry communities. 
2. SCCs as anticancer agents 
Taking inspiration from the clinical success of 
the Pt(II) anticancer drug cisplatin [53, 54], SCCs 
themselves are under investigation as experimental 
cytotoxic anticancer agents. In the next sections, some 
of the most investigated systems are presented, 
including coordination and organometallic 
supramolecular systems, providing an idea of their 
main features and design principles.  
2.1. Cytotoxic palladium and platinum SCCs  
In palladium(II) and platinum(II) SCCs, the metal 
precursor can be cis-capped to allow only two 
coordination sites available for complexation to 
multidentate ligands to form discrete SCC 
architectures featuring square planar geometry 
around the metal centre [52]. For example, 2D 
dinuclear Pt(II) and Pd(II) metallacycles coordinated 
to amide-based dipyridyl ligands and 
1,1′-bis(diphenylphosphino) ferrocene ligands, have 
been studied as cytotoxic agents in vitro [55]. 
Interestingly, both metallacycles displayed increased 
antiproliferative effects compared to their metal 
precursors and organic ligands, suggesting that the 
structure of the intact metallacycle is essential for the 
observed activity [55]. Interestingly, the Pt(II)-based 
metallacycle was found to be a more potent inhibitor 
of cell proliferation against, head and neck, and 
thyroid cancer cell lines than cisplatin, and yet was 
less toxic against non-cancerous cells [55]. The 
mechanism of action of both metallacycles was 
investigated in vitro against the T98G brain tumor cell 
line [55], The results show that both compounds are 
easily internalized by the cancer cells, and induce 
oxidative stress eventually leading to cell death by 
apoptosis.  
 Concerning 3D supramolecular architectures, a 
highly charged [Pt6L4]12+ metallacage was studied for 
its antiproliferative activity [56], and it displayed 
similar cytotoxicity range as cisplatin towards a range 
of human cancer cell lines, while it was ca. 7-fold less 
toxic than cisplatin towards normal lung cells. 
Moreover, the cage was found to be localized inside 
the cell nucleus using atomic absorption spectroscopy 
[56]. It was also shown that the mechanism of action 
involves the compound’s non-covalent binding to 
DNA via intercalation.  
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Studies by Crowley and coworkers on the effect 
of different ligands (functionalized trispyridyl 
scaffolds with rigid alkene linker vs benzotriazoles, 
hexane-triazoles and PEG-triazoles-bisfunctionalised 
phenyl rings) on the biological activity of Pd2L4 
helicates have also been carried out, and showed a 
direct correlation between the stability of the helicate 
in biological media and its antiproliferative effects 
[57]. Similar [Pd2L4]4+ (L = 1,3-bis-hexanetriazole 
phenyl) helicates endowed with sufficient stability in 
aqueous environment were also found to be up to 
seven-fold more toxic (IC50 ca. 6 μM) than cisplatin 
against the cisplatin-resistant MDA-MB-231 breast 
cancer cell line after 24 h incubation [57], and cell 
death appeared to be induced by disruption of the cell 
membrane [57].  
Finally, examples of 3D metallacages, of the type 
Pd2L4, have also been reported as experimental 
anticancer agents either via tethering or encapsulation 
of a cytotoxic agent, exploiting the so-called prodrug 
concept. As a recent example, the conjugation of 
prodrugs to the surface of a 2D SCC has been 
described. Specifically, a supramolecular [Pt3L3]6+ 
hexagon was formed by self-assembly between a 
dinuclear Pt(IV) precursor and a bidentate ligand 
conjugated to organoplatinum species. The resulting 
supramolecular hexagons would deliver three 
equivalents of cisplatin upon reduction of the Pt(IV) 
prodrug in the intracellular environment (Figure 3) 
[58]. The antiproliferative effects of the 
supramolecular hexagon were tested against a range 
of cancer cell lines, sensitive or resistant to cisplatin, 
resulting in a more potent cytotoxic effect than 
cisplatin [58], even though no control with a Pt(IV) 
prodrug alone was reported. Mechanistic studies 
suggested that the prodrug induced apoptosis by 
causing DNA damage due to the intracellular release 
of cisplatin upon reduction of the Pt(IV) complex. 
Quantification of the intracellular Pt content 
suggested that the increased potency of the 
supramolecular hexagon was due to its higher cellular 
uptake compared to free cisplatin [58]. 
With the aim to exploit coordination-driven 
self-assembly to increase the anticancer potential of an 
adamantyl Pt(IV) prodrug, Lippard and coworkers 
used a tridentate ligand and a [PtII(ethane-1,2- 
diamine)] precursor to achieve a cationic [Pt4L6]12+ 
cage able to encapsulate the Pt(IV) complex [60]. Of 
note, the latter had low solubility in water (<500 μM) 
but became readily soluble when mixed with the cage. 
The hydrophobic adamantyl moiety of the prodrug 
molecule was postulated to be securely encapsulated 
within the hydrophobic cavity of the hexanuclear 
cage, as suggested by 1D and 2D NMR spectroscopy. 
The cage encapsulating the Pt(IV) complex was 
moderately cytotoxic in A549 human lung cancer 
cells, but still more potent than the Pt(IV) prodrug and 
of the hexanuclear Pt(II) cage alone [60]. The 
mechanistic hypothesis is that the Pt(IV) complex is 
reduced intracellularly by ascorbic acid, thus, 
releasing cisplatin, 1-adamantylamine, and succinic 
acid, as suggested by NMR spectroscopy and mass 
spectrometry methods. 
 
 
Figure 3 – A) Schematic representation of a [Pt3L3]6+ hexagon exo-functionalised with three moieties of a Pt(IV) prodrug [58]. B) The amphiphilic polymer 
Pt-PAZMB-b-POEGMA, containing glutathione (GSH)-responsive deblock copolymers as the arms and an aggregation-induced emissive Pt(II) metallacycle as the 
core unit [59]. 
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 Further studies on a similar water soluble 
[Pt4L6]12+ metallacage, forming drug-loaded 
nanoparticles with an anionic polymer, revealed that 
the fluorophore fluorescein could also be 
encapsulated within the cavity [61]. Thus, the 
fluorescein moiety was conjugated to a Pt(IV) prodrug 
and encapsulated in the metallacage, and the cellular 
uptake and release of the guest prodrug could be 
studied in HeLa cells in vitro by fluorescence 
microscopy [61]. The necessity of optimizing the 
formulation of SCCs for drug delivery via formation 
of nanoparticles has also been elegantly addressed by 
Stang and coworkers using covalent conjugation of a 
polymer to formulate a Pt(II)-based supramolecular 
metallacycle into 50 nm nanoparticles, formed by 
self-assembly, for the delivery of doxorubicin (DOX) 
[59]. The resulting Pt-PAZMB-b-POEGMA 
amphiphilic polymer is shown in Figure 3B. The 
impacts of the morphology and size of the 
supramolecular assemblies on their endocytic 
pathways, uptake rates and efficiency, as well as 
cytotoxic effects were also investigated in vitro [59]. To 
evaluate the in vivo antitumor efficacy, HeLa 
tumor-bearing mice were intravenously injected with 
the DOX-nanoformualation (5.00 mg DOX/kg, 0.150 
mg Pt/kg) and showed enhanced tumor reduction 
with respect to free DOX, while presenting low 
systemic toxicity [59]. 
2.2. Cytotoxic ruthenium(II)-arene SCCs 
Biologically active Ru-based coordination and 
organometallic complexes [62] have recently 
prompted analogous studies of ruthenium(II)-arene 
supramolecular coordination complexes with a 
particular focus on their anticancer properties. 
Typically, ruthenium(II) ions (d6 electronic 
configuration) adopt a hexa-coordinated octahedral 
coordination geometry. Hence, in order to produce 
discrete supramolecular entities, rather than extended 
coordination polymers or MOFs, an auxiliary ligand is 
needed to block some of the several Ru(II) 
coordination sites. In most cases, this is achieved by 
using dinuclear piano-stool ruthenium(II)-arene 
“clip” complexes linked together via pyridine 
containing multidentate ligands, to form a range of 3D 
and 2D supramolecular polyhedra [63-69]. These 
metalla-assemblies possess different functional 
groups, situated either at the periphery or at the core 
of the assembly. 
Supramolecular ruthenium(II) metallacycles 
were already reported in the late 1990’s and displayed 
properties, such as water solubility and stability, 
which make them suitable for biological applications. 
It was initially postulated that cytotoxicity associated 
with supramolecular Ru(II) complexes was due to 
their intracellular dissociation, and subsequent 
binding of the released ruthenium cations to proteins 
and DNA, causing extensive cell damage and 
apoptosis [64]. Interestingly, these complexes have 
been shown to cause cell death also by triggering 
excessive autophagy, the controlled process of 
recycling dysfunctional or destroyed proteins and 
organelles via lysosome digestion [70]. Within a series 
of ruthenium(II)-arene metallarectangles with 
different paneling linkers, one derivative has been 
shown to be moderately cytotoxic in vitro against 
multidrug resistant human colon cancer cells 
(HCT-15/CLO2, IC50 ca. 16.5 μM) compared to 
cisplatin and doxorubicin [63], suggesting that the 
mechanism of cytotoxic action of these 
supramolecular structures is different from those of 
classical anticancer metallodrugs and requires further 
investigation.  
Similarly to metallacycles, ruthenium(II)-arene 
metallabowls have also been developed and tested for 
their antiproliferative properties in vitro against a 
range of cancer cell lines (colorectal, gastric, and liver 
cancer cells) [69-71]. Among them, a metallabowl 
featuring 8-dihydroxy-1,4-naphthaquinonato ligands 
was two-fold active than both cisplatin and 
doxorubicin against HCT-15 cells [69]. Further 
investigations showed that, upon metallabowl 
exposure, the expression of two known colorectal 
cancer suppressors, p53 and the Adenomatous 
polyposis coli (APC) gene, increased in HCT-15 cells 
[69, 71].  
By introducing tridentate, planar ligands to the 
binuclear arene Ru(II) “clips”, a range of hexanuclear 
3D Ru(II) metallacages have been reported by 
variation of the paneling linker ([Ru2(p-iPrC6H4Me)2 
(OO∩OO)][CF3SO3]2 (OO∩OO = 2,5-dioxydo-1,4- 
benzoquinonato [dobq], 5,8-dihydroxy-1,4- 
naphthaquinonato (donq), and 6,11-dihydroxy-5,12- 
naphthacenedionato [dotq] etc.)) [72-75]. Among 
them, the dinuclear “clip” containing donq as the 
bridging ligand was a moderate inhibitor of cell 
viability against a range of cancer cell lines (25 < IC50 < 
90 μM), whereas all the other tested metallacages 
were non-cytotoxic [64, 76]. Alongside ruthenium- 
arene complexes exhibiting antiproliferative effects 
per se, the synthesis of three new pyrenyl-containing 
dendrimers and their encapsulation into a 
water-soluble hexaruthenium(II)-arene metallaprisms 
was achieved, and the resulting host-guest systems 
were shown to possess enhanced antiproliferative 
effects in cancer cells in vitro with respect to the free 
components [77].  
2.3. DNA Targeted SCCs 
Most of the numerous cytotoxic SCCs mentioned 
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in previous sections were not designed to specifically 
target cancer cells, thus, leading to possible side 
effects. With the aim to develop tumor directed SCCs, 
the chirality of some of these scaffolds was exploited 
to direct molecular recognition of specific biological 
targets, namely nucleic acids. Within the helicates 
family, Hannon and coworkers developed the 
synthesis of ‘cylinders’, dinuclear triple-helical 
compounds which are prepared in a single step from 
a pyridyl-aldehyde, a diamine and an octahedral 
metal (usually Fe(II) or Ni(II) ) (Figure 4A) [78]. The 
cylinders differ from earlier helicates also since they 
are endowed with certain rigidity along the length of 
the structure, due to π-stacking interactions between 
the rings of the diphenylmethane ‘spacer’. By 
contrast, the Lehn helicate systems comprise 
bipyridine ligands linked by flexible alkyl or 
alkylether chains, introducing a higher degree of 
flexibility into the helical structure [79, 80]. 
A first study investigated the mode of binding of 
a binuclear Fe(II) triple-stranded cylinder to a DNA 
model by NMR spectroscopy and computational 
modelling techniques [81]. The obtained results 
suggested that the cylinder binds to the DNA major 
groove. It was also revealed that although a racemic 
mixture of the chiral helicate was introduced to the 
double stranded oligonucleotide, only the 
M-enantiomer was able to bind DNA causing a 
change in its conformation [81]. The mode of binding 
of the Fe(II) cylinder was further studied and revealed 
that the helix preferentially binds to short (8-10 base 
pairs) purine-pyrimidine tracts within the DNA 
sequence [82]. The affinity for specific DNA sequences 
proved a promising feature to target cancer cells via 
binding of the helicates to oncogenes [82].  
Later on, it was also discovered that Fe(II) 
cylinders have a high specificity for RNA 3-way 
junctions [62], as well as for certain non-canonical 
secondary DNA structures, such as DNA bulges [83, 
84] and G-quadruplex DNA (G4) [85]. In particular, 
targeting telomeric G4s and stabilization of these 
structures has been shown to inhibit telomerase 
activity, leading to cell death [86]. To that end, a pair 
of enantiomeric Fe(II) helicates which were soluble in 
aqueous media were synthesized, and their affinity 
for human telomeric G4s was assessed [85]. The 
P-enantiomer Fe(II) helicate was found to bind 
strongly and selectively to the G4, whereas the 
M-enantiomer showed no association. Furthermore, 
the strong binding affinity to G-quadruplex DNA 
translated into strong inhibition of telomerase 
activity.  
Triple stranded “Y-shaped” junctions are an 
example of another non-canonical DNA structure 
which form during DNA transcription and 
replication, and whose regulation may allow to 
achieve antiproliferative effects and, most 
importantly, cell cycle control. Several studies have 
shown that these structures can be targeted by 
binuclear metallahelicates (Fe(II) and Ru(II)-based) 
[23, 82, 84, 87-90]. In 2010, Hannon and coworkers 
showed that the stabilization of Y-shaped junctions by 
supramolecular Ru(II) cylinders severely inhibits the 
function of polymerase enzymes, accounting for their 
cytotoxicity [88]. This study provides crucial evidence 
that the non‐covalent DN A  bind ing of the  cylinders 
can indeed affect the ability of proteins to process the 
DNA information. Further studies of DNA binding of 
Fe(II) helicates revealed that, to facilitate strong 
binding to the major groove of duplex DNA, a rigid 
helicate is preferred over the analogous flexible 
helicates [91]. The former was also a potent cytotoxic 
agent against cisplatin resistant human ovarian 
carcinoma cells [91]. 
In addition to Fe-based helicates, the 
self-assembled platinum(II) molecular square 
[Pt(en)(4,4′-dipyridyl)]4 (en = ethylenediamine) has 
been reported to be an efficient G-quadruplex binder 
and telomerase inhibitor (Figure 4B) [92]. Molecular 
modeling studies combined to molecular dynamics 
(MD) calculations suggested that the square 
arrangement of the four bipyridyl ligands, the highly 
electropositive nature of the overall complex, as well 
as hydrogen bonding interactions between the 
ethylenediamine ligands and phosphates of the DNA 
backbone all contribute to the observed strong 
binding affinity to the G4 (Figure 4B). More recently, a 
supramolecular [Pt2L2]6+ binuclear metallacycle with 
large, planar 2,7-diaza-pyrene-based ligands has been 
explored for its DNA binding properties [94]. This 
interaction caused DNA bending, which in turn 
prevented DNA processing and replication. 
Moreover, the metallacycle exhibited antiproliferative 
effects in cancer cells and different spectrum of 
activity with respect to cisplatin [94]. Supramolecular 
Pt(II) quadrangular boxes with L-shaped 
4,4′-bipyridine ligands were also shown to bind 
duplex and G-quadruplex DNA motifs in a 
size-dependent fashion [95]. Specifically, three 
dinuclear Pt(II) molecular squares of distinct size 
(ranging between 110-220 Å) inhibited cancer cells’ 
growth and heavily influenced the expression of 
genes known to form G-quadruplexes in their 
promoter regions. Interestingly, the smallest Pt-box 
displayed less activity, but enhanced selectivity for 
the G4 promoter c-Kit, as shown by FRET 
(Fluorescence Resonance Energy Transfer) DNA 
melting assays [95]. 
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Figure 4 - A) Schematic representation and corresponding X-ray structures of a cylindrical [Ni2L3]4+ helicate (CCDC n° 722438) [78] and a [Fe2L3]4+ helicate 
(CCDC n° 622770); B) Schematic representation of a multinuclear Pt(II) metallacycle acting as quadruplex binder and telomerase inhibitor and its adduct with a G4 
structure studied by molecular modeling [92] (Adapted with permission from ‘J. Am. Chem. Soc. 2008, 130 (31), 10040-10041’. Copyright 2008 American Chemical 
Society.); C) Schematic representation of a Ru8 cage bearing porphyrin ligands studied as nucleic acid binder [93].  
 
Finally, 3D SCCs, including boxes and cubes, 
have been reported to be able to interact with nucleic 
acids. For example, porphyrin-based scaffolds were 
designed and linked via ruthenium complexes used as 
bridging blocks able to connect two porphyrin units 
and create octa-ruthenium supramolecular cubes 
(Figure 4C) [93]. The G4 binding properties of the 
cubes were studied by different techniques, including 
fluorescence intercalation displacement (FID) and 
surface plasmon resonance, and the obtained results 
showed strong interactions with different G4 models, 
but also scarce selectivity with respect to duplex 
DNA.  
2.4. Metalla-assemblies as PDT agents 
In traditional photodynamic therapy (PDT), a 
photosensitizer interacts with oxygen to produce 
reactive oxygen species (ROS) upon light activation. 
ROS induce cell death via different pathways, 
including extensive damage of unsaturated lipids 
and certain amino acid side chains as well as of the 
nitrogenous bases of nucleic acids. PDT is considered 
a promising treatment as it possesses several benefits 
in comparison to common cancer therapies [96]. 
However, this technique is still limited due to a 
number of drawbacks, generally associated with a 
residual photosensitivity after PDT treatment, 
difficulty to treat metastases, the need of light at a 
specific wavelength to be able to reach deeper 
tumors, as well as an adequate tissue oxygenation. 
For example, several ruthenium-arene 
metalla-assemblies coupled to photosensitizers, 
including porphyrins, were prepared and tested as 
PDT agents [97]. Recently, Therrien and coworkers 
have synthesized an anthracene-based 
metalla-rectangle with the idea to improve the cell 
uptake of the photosensitizer (anthracene) [98]. In the 
presence of oxygen and light activation, anthracene 
forms an endoperoxide intermediate. The 
endoperoxide formation is reversible, and oxygen can 
be released in a different environment. 
Unfortunately, upon formation of the metalla- 
assembly, the propensity of the anthracene moiety to 
react with oxygen to form endoperoxide derivatives 
was lost [98]. 
Noteworthy, in this area, Borondipyrromethene 
(BODIPY) is a class of fluorescent dyes used for many 
applications such as light harvesting, imaging, in 
solar cells and for PDT [99-101]. Thus, BODIPY-based 
palladium, platinum, iron, and zinc supramolecular 
structures have been synthesized by self-assembly 
and analysed for their host–guest chemistry and 
biological properties.[102-104] Inspired by these 
properties of BODIPY-based supramolecules, Gupta, 
Lee and coworkers designed, synthesized, and 
studied for their antiproliferative activities new 
ruthenium and iridium metalla-rectangles featuring a 
BODIPY-based linker (Figure 5) [103, 105]. Confocal 
laser scanning microscopy studies suggested that the 
compounds use a cytoplasmic mechanism of action in 
causing cell death. Additionally, binding studies 
revealed the ability of compounds to interact with 
both DNA and protein [105]. However, the possibility 
of using such metalla-rectangles as PDT agents 
remains to be explored.  
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Figure 5 - X-ray structures of rectangles (A) [2]4+ and (B) [4]4+ from ref. [105]. 
 
One of the first examples of a SCC featuring a 
BODIPY ligand for applications as theranostic agent 
was reported by Cook and coworkers [106], who 
investigated the coordination-driven self-assembly of 
two novel Pt(II) supramolecular triangles containing 
a pyridyl-functionalized BODIPY ligand. While the 
Pt(II) moieties can also act as cytotoxic agents, the 
BODIPY cores within triangles enable their transport 
within cancer cells to be visualized by confocal laser 
scanning microscopy. Moreover, the BODIPY ligands 
also form the basis for use as a photosensitizer for 
photodynamic therapy (PDT). The obtained results 
showed that the combination of PDT and 
chemotherapy greatly enhances anticancer efficacy 
through a synergistic therapeutic effect, particularly 
against drug resistant cancer cells in vitro [20]. 
3. SCCs as drug delivery systems for 
anticancer agents 
The focus of this chapter is on SCCs that show 
promise for biomedical applications not due to their 
intrinsic anticancer potential, but for their favorable 
properties as drug delivery systems. This is 
particularly relevant to cancer chemotherapy, whose 
success rate remains limited, primarily due to scarce 
selectivity of drugs for the tumor tissue, often 
resulting in severe toxicity and in the development of 
drug resistance. So far, lipid nano-systems, such as 
liposomes and micelles, along with virus-inspired 
vectors and polymeric particles, dendrimers as well as 
inorganic nanoparticles, have been studied to deliver 
bioactive compounds to tumor sites. However, such 
targeted constructs have several limitations: for 
example, polymers and dendrimers often require 
considerable synthetic effort and can be plagued by 
low yields and largely amorphous final structures, 
while nanoparticles often present issues of toxicity 
and lack of biodegradability [107].  
In this context, supramolecular metallacages 
feature a number of properties that make them 
attractive candidates for future drug delivery systems. 
For example, the rigid, porous structure offers a 
secure cavity for small drug molecules, to protect 
them from metabolism, and the ability to modify the 
ligand structure both pre- and post- self-assembly 
allows for the properties of the resulting cage to be 
improved. Furthermore, since metallacages, at 
variance with MOFs, are discrete chemical entities, the 
issues of solubility in an aqueous environment can be 
potentially overcome. Despite these attractive 
features, SCC drug delivery is still in its infancy [108].  
Overall, SCC as drug delivery systems can be 
based on i) both encapsulation of a drug, driven by 
hydrophobicity of the cargo drug molecule and the 
host cavity, and non-covalent interactions within the 
host cavity (e.g. H-bonding, van der Waals), as well as 
ii) covalent bonding of a prodrug species to the SCC 
architecture. In the latter case, the prodrug can then be 
cleaved and activated via external chemical stimuli to 
allow drug release in a controlled manner. In this 
chapter, representative examples of both strategies are 
provided. 
Based on previous studies on ruthenium(II) 
metallacycles in 2008 [109], pioneering work by 
Therrien and coworkers on SCCs as drug delivery 
systems focused on the study of water soluble 
hexaruthenium metallacages (metalla-prisms) able to 
encapsulate lipophilic molecules.[29] Thus, the 
cationic hexanuclear metalla-prism [(p-cymene)6Ru6 
(tpt)2(dhbq)3]6+ (tpt = 2,4,6-trispyridyl-1,3,5-triazine; 
dhbq = 2,5-dihydroxy-1,4-benzoquinonato) was 
shown to encapsulate two hydrophobic PdII and PtII 
complexes [M(acac)2] (M = metal, acac = 
acetylacetonato) (Figure 6) [29]. While the [M(acac)2] 
complexes are completely inactive due to their 
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inherent lack of solubility in water, the metalla-prism 
is water soluble and moderately cytotoxic (IC50 ca. 23 
μM) against human ovarian A2780 cancer cells. This 
initial study provided the proof-of-concept for the 
so-called “Trojan horse strategy” of protecting a 
cytotoxic agent in the cavity of a metallacage until, 
after cell uptake, the drug can be released and 
perform its cell-killing activity. In fact, the 
encapsulated [Pd(acac)2] - ([Pd(acac)2]⊂[(p-cymene)6 
Ru6(tpt)2(dhbq)3]6+]) - was 20-fold more cytotoxic (IC50 
ca. 1 μM) than the empty metalla-prism [29].  
Following these promising results, a 
hexaruthenium metallacage of the type [Ru6(p- 
iPrC6H4Me)6(tpt)2(C6H2O4)3]6+ was investigated for the 
release mechanism of encapsulated fluorescent 
pyrene derivatives and for its anticancer properties in 
vitro [28]. The obtained results showed that, while the 
free pyrene derivative and the cage complex alone 
were scarcely cytotoxic (IC50 ca. 16 µM or higher), the 
host-guest complex was considerably more active 
(IC50 ca. 6 µM) [28]. The increased cytotoxicity of the 
water soluble cage-pyrene complex was due to an 
increased uptake of the overall system as shown by 
fluorescence microscopy. Of note, the fluorescence of 
the pyrene derivatives is quenched upon 
encapsulation, allowing for the release of the molecule 
to be monitored by fluorescence spectroscopy [28]. In 
further studies, the encapsulation properties of the 
hexaruthenium metallacage with a series of 
functionalized fluorescent pyrene derivatives was 
characterized using NMR (1H, 2D, DOSY) 
spectroscopy and electrospray ionization mass 
spectrometry (ESI-MS) [110]. The antiproliferative 
properties of the vacant cage and the pyrene-cage 
complexes were studied in A2780 ovarian cancer cells, 
and the host-guest complexes showed the lowest IC50 
values [110]. The study also demonstrated that the 
hexaruthenium cage complexes can improve the 
efficacy of insoluble inhibitors in vitro. 
The effect of the portal size of the hexaruthenium 
metallacage complex on the retention of the planar 
guest molecules, [Pd(acac)2] complex and 
1-(4,6-dichloro-1,3,5-triazin-2-yl)pyrene, was also 
investigated [113]. Thus, three hexaruthenium cages 
were prepared by extending the polycyclic aromatic 
system in the di-ruthenium bridging ligands, using 
the 1,4-naphthoquinonato, 1,4-anthraquinonato, and 
5,12-naphthacenedionato analogues, which 
progressively decreased the portal size of the cage, 
while the internal cavity remained largely the same. 
The host-guest properties of these water-soluble 
supramolecular drug delivery systems were studied 
in solution by NMR and fluorescence spectroscopy. 
The results showed that the complex with the largest 
pore size (estimated to be approximately 7.4×10.2 Å 
by molecular modeling) is more stable, suggesting 
that a larger pore size facilitates the entrance of the 
guest molecule in the cage, while the smaller pore size 
retains the guest molecule more effectively [113]. 
Inductively Coupled Plasma Mass Spectrometry 
(ICP-MS) and fluorescence microscopy allowed to 
assess that all cages deliver the host to intracellular 
organelles and the mechanisms of uptake involve 
endocytosis/macropinocytosis rather than passive 
diffusion across the cell membrane [113]. 
Other examples of SCCs as drug delivery 
systems, based on other transition metals, include 
surface functionalized porous coordination nanocages 
of Cu(II) and 5-(prop-2-ynyloxy)isophthalic acid (pi), 
bearing a water solubilizing polymer (PEG5k), which 
were synthesized using a “click chemistry” approach 
[114]. The scaffold is composed of 12 di-copper 
paddlewheel clusters and 24 isophtalate moieties, 
with 8 triangular and 6 square windows that are 
roughly 8 and 12 Å across, respectively. The internal 
cavity has a diameter of ca. 15 Å and the cage has high 
stability in aqueous medium. In addition, the cages’ 
drug loading and release capacity has been evaluated 
using the anticancer drug 5-fluorouracil (5-FU) [114]. 
Drug release experiments were carried out by 
dialyzing the drug-loaded Cu(pi)-PEG5k against 
phosphate buffered saline (PBS) solution at room 
temperature. Interestingly, around 20% of the loaded 
drug was released during the first 2 hours, while a 
flatter release curve can be observed up to 24 hours. 
The slow release has been associated to the slow 
diffusion rate of 5-FU caused by the strong interaction 
between Lewis acid sites in Cu(pi) and basic site of 
5-FU. 
Based on previous work by Fujita and coworkers 
[115], and within the M2L4 cage family, Crowley et al. 
designed a cationic [Pd2L4]4+ cage using 
(2,6-bis(pyridin-3-ylethynyl)pyridine) as the bidentate 
ligand, and characterized the 3D system by various 
methods, including 1H NMR spectroscopy, ESI-MS 
and XRD [111]. Interestingly, the encapsulation of the 
anticancer drug cisplatin within the metallacage 
cavity, lined with the nitrogen atom from the central 
pyridine of the ligand, was demonstrated by XRD 
studies, revealing that two molecules of the drug 
could be contained (Figure 6) [111]. The release of 
cisplatin was facilitated by the introduction of 
competing ligands (4-dimethylaminopyridine or Cl-) 
to disassemble the cage, as shown by 1H NMR and 
ESI-MS. Unfortunately, while the cisplatin-cage 
host-guest complex formed in acetonitrile and DMF, 
in more hydrogen bond competitive solvents (water 
and DMSO) no host-guest interaction was observed 
[116]. Additionally, the parent Pd(II) based cage 
decomposed rapidly in the presence of nucleophiles. 
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In fact, the same group demonstrated that the 
stability of [Pd2L4]4+ cages when exposed to biological 
nucleophiles highly depends on the ligand structure: 
specifically, triazole-based ligands were found to lead 
to significantly more stable metallacages in 
comparison with pyridine-based scaffolds [57]. 
More recently, Casini and coworkers explored 
similar cationic [Pd2L4]4+ systems featuring 
bis(pyridyl) ligands – of general scaffold 
3,5-bis(3-ethynylpyridine)phenyl) - and developed 
the exo-functionalization of the ligand to add different 
groups, including fluorescent tags facilitating the 
study of the cellular accumulation of these systems by 
fluorescence microscopy [117, 118]. Structural studies 
by 1H NMR ad XRD were performed demonstrating 
encapsulation of cisplatin (Figure 6) [119]. Notably, 
most of the reported metallacages and their 
precursors were non-toxic in healthy rat liver tissue ex 
vivo, making them suitable for application as drug 
delivery systems [120]. Furthermore, the cytotoxicity 
of the [Pd2L4]4+ cages have been tested in vitro against 
a small panel of human cancer cells, showing scarce or 
moderate antiproliferative activities depending on the 
ligand scaffold [120]. More importantly, the activity of 
encapsulated cisplatin in the benzyl 
alcohol-exo-functionalized Pd(II) cage was evaluated 
against SKOV-3 ovarian cancer cells, showing a 
marked increase in cytotoxic potency (IC50 = 1.9 ± 0.5 
µM) compared to free cisplatin (IC50 = 15.4 ± 2.2 µM) 
and the vacant cage complex (IC50 = 11.6 ± 1.7 
µM).[120] Interestingly, the aromatic and highly 
conjugated ligands confer the [Pd2L4]4+ cages 
fluorescence properties, which allowed to study their 
uptake in cancer cells by fluorescence microscopy.  
Water solubility and stability under 
physiological conditions are both crucial for the 
biological application of SCCs. Unfortunately, 
[Pd2L4]4+ cages of this type are scarcely soluble in 
water, despite their positive charge. Thus, there are 
different strategies to introduce water-solubility to the 
SCCs. The most straight-forward approach is a simple 
anion exchange, since the SCCs usually are positively 
charged complexes. It was shown, that the 
hexafluorophosphate salts of the aforementioned 
organometallic pillarplex SOCs, which are soluble in 
organic solvents like acetonitrile or 
dimethylformamide, can be easily converted into the 
corresponding acetates, which are extremely well 
water-soluble (> 1g / mL water) [45]. In case an anion 
exchange is not applicable or not leading to the 
desired effect, covalent modifications at the linker 
molecules can be performed to introduce polar 
functional groups, e.g. sulfonates [121]. Another 
strategy to increase the hydrophilic character of these 
systems has been demonstrated via the introduction of 
water soluble moieties in their scaffold, including 
PEG [122]. 
 
 
Figure 6 - A) Schematic representation and corresponding X-ray structure (CCDC n° 673229) of a [[Ru2L’]3L2]6+ cage encapsulating [PtII(acac)2] (acac = 
acetylacetonato) [29]. B) Schematic representation and corresponding X-ray structure (CCDC n° 853227) of an exo-functionalised [Pd2L4]4+ metallacage 
encapsulating two equivalents of cisplatin [111]. C) Schematic representation and corresponding X-ray structure (CCDC n° 902397) of a [Pd2L4]4+ capsule 
encapsulating two equivalents of corannulene [112].  
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The control of the host-guest properties of the 
cavity defined by the SCC is another essential feature 
to implement them for drug encapsulation. For 
example, anthracene-based Pt(II)- and Pd(II)-linked 
coordination capsules provide a characteristic 
spherical cavity – with a diameter of ca. 1 nm and a 
volume of ca. 600 Å3 - contoured by polyaromatic 
frameworks (Figure 6) [112, 123], and that can 
accommodate various neutral molecules, through 
hydrophobic and π-stacking interactions, in aqueous 
solution [112, 123, 124]. Fluorescence microscopy 
studies allowed investigation of the intracellular 
accumulation of the capsules [124]. However, these 
systems, even without their guest molecules, manifest 
very pronounced cytotoxic effects, which make them 
unsuitable for drug delivery. Interestingly, the 
observed trends in the anticancer activity of the 
capsules and their host-guest complexes correlate 
with their different stabilities toward glutathione, 
estimated by NMR-based kinetic experiments [124]. 
The data suggest the glutathione-triggered 
disassembly of the capsular structures in cells as a 
potential activation pathway for their cytotoxic 
activity.  
For supramolecular metallacages, such as 
[Pd2L4]4+, with a molecular weight of ca. 2-3 kDa and 
diameter of ca. 10-15 Å, passive tumor targeting via 
the enhanced permeability and retention (EPR) effect 
is not likely to influence their delivery [125]. 
Furthermore, it should be mentioned that the success 
in preclinical in vivo studies of drug accumulation in 
tumors due to the EPR effect has so far not translated 
into success in clinical trials [126]. In this context, 
active tumor targeting mechanisms are crucial to 
achieve selectivity of metallacages for cancerous cells, 
for example via the conjugation of cancer-cell-specific 
ligands. However, this concept has been scarcely 
explored so far and few examples of bioconjugated 
cages are available in the literature. One study 
showed non-covalent peptide coating on 
self-assembled M12L24 coordination spheres [127], 
while encapsulation of a protein within a Pd12L14 cage 
has been achieved by appropriate 
endo-functionalization of the ligands [128]. Of note, 
the latter was the first example of encapsulation of a 
protein within synthetic host molecules which may 
unveil new strategies to deliver proteins at specific 
site and to control their function [128]. In this latter 
example, ligands were first tethered to the protein and 
then the cage was reconstituted via self-assembly 
upon addition of other ligands and metal precursors.  
Within this framework, in 2017 Casini and 
coworkers reported on the first example of 
bioconjugation of self-assembled [Pd2L4]4+ cages via 
amide bond formation between the -COOH (or -NH2) 
exo-functionalized ligand/cage and a complementary 
residue on a model linear peptide [129]. Certainly, 
other types of exo-functionalization, other than amide 
bond formation, for tethering metallacages to 
peptides or antibodies should be investigated, 
including click chemistry approaches [130]. 
Afterwards, in a proof-of-concept study, the same 
group reported on [Pd2L4]4+ cages conjugated via 
amide bond to four ligands selective for binding to 
integrins αvβ3 or α5β1 [131]. The conjugated cages 
were first studied for their integrin recognition 
properties using an ELISA assay, and were 
demonstrated to maintain high binding affinity and 
selectivity. Cage formation and encapsulation of 
cisplatin was proven by 1H NMR, 1H DOSY and 195Pt 
NMR spectroscopy. Upon encapsulation, cisplatin 
showed increased cytotoxicity in vitro, in melanoma 
A375 cells overexpressing αvβ3 integrins, while it was 
not active against A549 human lung cancer cells, not 
expressing this specific integrin [131]. Moreover, ex 
vivo studies in tissue slices indicated reduced toxicity 
towards healthy liver and kidney tissues for 
cage-encapsulated cisplatin. The reason for such 
reduced toxicity is that the encapsulated drug is less 
accumulated in these organs compared to the ‘free’ 
one, as demonstrated by the analysis of metal content 
by ICP-MS [131]. It should be noted that anchoring of 
the peptide to the metallacages also allowed to 
substantially increase their solubility in aqueous 
environment. In general, it is worth mentioning that 
targeting supramolecular metal-based complexes to 
the desired site is essential to control off-target effects 
of the delivered chemotherapic agent, as well as to 
reduce the possible intrinsic systemic toxicity of the 
supramolecular metal-based drug delivery system. 
4. In vivo activity of anticancer and 
diagnostic SCCs 
Although the field of supramolecular 
coordination complexes as anticancer therapeutics is 
still in its infancy, a few preliminary in vivo 
experiments have been carried out. For example, the 
anticancer activity of two cytotoxic Ruthenium(II)- 
arene metallacycles, one with a 2D rectangular 
geometry and one featuring a metallabowl geometry 
(Figure 7A), was studied in vivo [70], using a hollow 
fiber assay, whereby a semipermeable fiber 
impregnated with the human colorectal carcinoma 
HCT-15 cells were implanted into the intraperitoneal 
and subcutaneous compartments of nude mice [70]. 
The two ruthenium-arene SCCs were then 
administered to the impregnated nude mice, and the 
animals were left for 7 days before the hollow fibers 
were removed and the tumors examined. The study 
revealed that the metallabowl-type metallacycle was a 
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more potent inhibitor of cancer cells growth than the 
metallarectangle. However, both these 
ruthenium-arene scaffolds were not as effective 
inhibitors of cell proliferation as cisplatin in the 
hollow fibers located in the intraperitoneal and 
subcutaneous regions of the host mice [70]. The 
mechanism of induced cell death was investigated 
and the study revealed that both metallacycles 
induced autophagy in HCT-15 cells, and again the 
metallabowl was more potent than the 
metallarectangle, in line with the observed enhanced 
anticancer activity [70].  
Concerning platinum(II) SCCs, in addition to the 
above mentioned Pt-PAZMB-b-POEGMA 
amphiphilic polymer by Stang and coworkers [60], a 
luminescent 2D Pt(II) metallacycle of rhomboidal 
geometry has also been studied in vitro and in vivo for 
its anticancer activity (Figure 7B) [132]. Of note, the 
compound remained intact upon cellular 
internalization and did not photobleach under the 
conditions of the confocal microscopy experiment. 
Preliminary in vitro studies against lung (A549) and 
cervical carcinoma (HeLa) cells confirmed rapid 
cellular uptake of the platinum metallacycle [132]. 
Afterwards, a mouse tumor xenograft model, 
generated using nude mice injected in the 
subcutaneous region with MDA-MB-231human 
breast cancer cells, was selected for the in vivo study. 
The tumors were allowed to reach a volume of 200 
mm3 before drug administration. Mice were treated 
with a solution (300 μL) of Pt-metallacycle at a 
concentration of 0.6 mg/mL, administered via 
intraperitoneal injection every 3 days for 30 days. The 
study revealed that at the end of the treatment, a 64% 
median tumor volume reduction was observed in 
treated mice with respect to controls. Furthermore, 
the tumor growth inhibition, measured by the change 
in volume of the tumor throughout the length of the 
experiment and defined by the T/C ratio (in %, 
corresponds to the ratio between the Treatment (T) 
over the Control (C)),[133] was calculated as 36%, well 
below the National Cancer Institute standard (as the 
lower threshold for tumor inhibition of <42%)) [134]. 
Very recently, Chen, Stang and coworkers 
developed a sophisticated porphyrin-based 
metallacage through multicomponent coordination- 
driven self-assembly, acting as a theranostic platform 
to fabricate metal nanoparticles (MNPs) [135]. In 
details, a discrete platinum(II) metallacage was 
synthesized, using therapeutic cis-(PEt3)2Pt(OTf)2 
(cPt), 5,10,15,20-tetra(4-pyridyl)porphyrin (TPP) and 
disodium terephthalate (DSTP) as the building blocks, 
with the idea achieving synergistic anticancer efficacy 
(Figure 8). Of note, both the fluorescence emission 
and 1O2 generation quantum yield of the porphyrins 
were dramatically increased upon formation of 
MNPs, which was favorable for both NIRFI and PDT 
[135]. Furthermore, the nano-formulation was 
functionalized by two amphiphilic diblock polymers 
(mPEG-b-PEBP and RGD-PEG-b-PEBP). The resultant 
MNPs exhibited long blood circulation time and high 
tumor accumulation benefiting from the EPR effect 
and active targeting ability. Indeed, superior tumor 
suppression with respect to separate cisplatin 
treatment and light irradiation was realized without 
recurrence after single-dose injection of the targeted 
MNPs in xenograft models of tumors from αvβ3 
integrin overexpressing U87MG cells and 
cisplatin-resistant human ovarian cancer A2780cisR 
cells [135]. Moreover, in order to verify the in vivo 
anti-tumor performance and anti-metastasis effect of 
photochemotherapy, 4T1 (breast cancer) tumors were 
orthotopically inoculated in the mammary fat pads to 
produce spontaneous metastases in the lung, which 
was an experimental animal model for stage IV 
human breast cancer. 
 
 
Figure 7 - Schematic representations of A) two arene-Ru(II) metallacycles (left: 2D rectangular geometry; right: ‘metalla-bowl’ geometry)[70] and of B) a 
rhomboidal Pt(II) metallacycle,[132] studied in vivo for their anticancer properties. 
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Figure 8 – A) Schematic diagrams of the MNPs serving as a multifunctional theranostic platform. Structures of TPP, cPt, DSTP, M, mPEG-b-PEBP, and RGD-PEG- 
b-PEBP [135]. B) Ex vivo image of the main organs separated from U87MG tumor-bearing mice at 24 h post injection of MNPs. C) PET image of U87MG 
tumor-bearing nude mice at 2, 4, 6, 12, 24 and 48 h post injection of 64Cu@MNPs (150 μCi). The white circle denotes the tumor site. D) In vivo T1-weighted axial MRI 
images (7T) of the mice pre-injection and after injection of Mn@MNPs. The white circle denotes the tumor site. (Adapted with permission from ‘Nature Comm. 2018, 
9, 4335-4335’, licensed under a Creative Commons Attribution 4.0 International License. Copyright 2018 Springer Nature Publishing AG.) 
 
Notably, the combination of chemotherapy and 
PDT using the supramolecular MNPs exhibited 
superior anti-tumor efficacy with a 93.5% reduction in 
tumor volume, with respect to the least effective, and 
undergoing tumor recurrence during treatment, 
separate chemotherapic and PDT treatments [135]. 
Excellent anti-metastatic effect was also achieved, 
which was attributed to the synergistic 
photochemotherapy. In addition, by chelating a 
positron emitting metal ion (64Cu) or a paramagnetic 
Mn ion, the 64Cu@MNPs (or Mn@MNPs) were shown 
to be excellent PET imaging and MRI agents, allowing 
precise diagnosis of tumor and real-time monitoring 
of delivery, biodistribution and excretion of the MNPs 
(Figure 8) [135]. In fact, significant tumor 
accumulation was clearly visible in the U87MG 
tumor-bearing mice administered with MNPs at 6 h 
post injection, and exceptionally intensive signal was 
visible in the tumor area for more than 24 h in 
comparison with other tissues. Overall, these exciting 
preliminary in vivo studies highlight the potential of 
SCCs as anticancer agents and constitute the blueprint 
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of next generation nanomedicines. 
Finally, using a kinetically robust CoIII4L6 (L = 
tetrahedron), Lusby and Archibald and coworkers 
showed the feasibility of encapsulating the γ-emitting 
[99mTc]TcO4– anion - the most widely used precursor in 
clinical nuclear diagnostic imaging - under conditions 
compatible with in vivo administration [136]. 
Subsequent single-photon emission computed 
tomography (SPECT) imaging of the caged-anion 
revealed a marked change in the biodistribution of the 
host-guest system compared to the thyroid- 
accumulating free oxo-anion (Figure 9). While this 
example still needs optimization, including targeting 
to disease tissues, the obtained results move clinical 
applications of (metallo)supramolecular species a step 
closer. 
5. Summary and Future Perspectives 
During the past decade, increasing interest has 
been manifested in the design and synthesis of 
discrete metallo-supramolecular architecture for 
biomedical applications. Certainly, the examples 
reported in this review show that SCCs can be 
designed to feature an inherent bioactivity, i.e. to act 
as a cytotoxic metallodrug itself. There are several 
possible ways to include bioactivity in SCCs, either by 
the metals (e.g. upon metal release / disassembly of 
the SCC / photoactivation) or by biological activity of 
the organic linker molecule. Also, the structural 
prerequisites and the outer shape of the SCCs can 
significantly determine their bioactivity as was shown 
for the metal helicates. The latter, due to their 
tetracationic charge and cylindric shape, can ideally 
interact with negatively charged biomolecules as 
DNA, and thanks to their intrinsic chirality, even 
recognize very selectively special structures like 
three-way junctions [137-143]. In addition, more 
complex architectures such as the interlocked 
metallacages reported by Clever et al. show a 
comparable interaction with DNA biomolecules [144]. 
Overall, these examples hold promise to achieve 
targeting by molecular design. 
In this context, the exact determination of the 
bioactive species (speciation) is very important, since 
for the modular built SCCs all individual components 
(metal ions, organic linkers), as well as decomposition 
products, can be potential cause of the observed 
activity. Therefore, the fine-tuning of the complex 
stability by linker-design (e.g. by using different 
donor moieties for linkers) in combination with the 
use of different (biologically active) metals are 
promising parameters for selectively influencing the 
bioactivity.  
 
 
Figure 9 – A) Structure of anion-binding CoIII4L6 cages shown exemplarily at the X-ray structure of a tetrahedral SCC, featuring an encapsulated ReO4– (CCDC n° 
1864366) [136]; B) Comparison of free [99mTc]TcO4– uptake in naïve mice (left) vs SCC-encapsulated [99mTc]TcO4– (right) monitored by SPECT imaging [136]. 
Encapsulation results in reduced thyroid and stomach uptake, and increased liver uptake. Images are maximum intensity coronal projections. S = Stomach, Th = 
Thyroid, L = Liver. (Adapted with permission from ‘J. Am. Chem. Soc. 2018, 140, 16877−16881’. Copyright 2018 American Chemical Society.)  
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Indeed, when developing supramolecular 
metal-based complexes for biomedical applications 
one should control their stability in physiological 
media and in the presence of biologically relevant 
nucleophiles or reducing agents [57, 132]. In general, 
the use of first row transition metals with prominent 
kinetic lability with respect to ligand exchange 
reactions, is not ideal to achieve robust systems in 
solution. Therefore, late transition metals such as 
Ru(II), Pt(II) and Pd(II) should be preferred. However, 
we envisage that the use of organometallic scaffolds, 
as in the case of SOCs, may be further exploited to 
increase the stability in biological environment of the 
resulting supramolecular systems. This feature would 
also be advantageous to reduce possible side-effects in 
vivo, including systemic toxicity due to off-target 
effects and extensive metal speciation. Within this 
framework, water-soluble NHC-based SOCs like the 
pillarplexes hold promise for application as 
metallodrugs (NHC complex character), drug- 
delivery systems (porous character) and diagnostic 
handles (in-built functionality: e.g. luminescence). 
Furthermore, this unique combination of properties 
renders organometallic supramolecular systems as 
highly potential candidates to investigate towards 
theranostic applications. 
In the previous sections, we have also 
emphasized the potential of 3D-metallacages as drug 
delivery systems for anticancer agents. In fact, cages 
have distinct advantages over conventional container 
molecules based on covalent bonds (e.g. nanotubes 
and polymeric nanoparticles), including the synthetic 
ease with which the coordination cages can be 
self-assembled, the availability of a large library of 
building blocks, and the possibility to design selective 
guest encapsulations. Despite these advantages, in 
order to develop the full potential of SCCs for 
biological applications, several issues need to be 
addressed. Firstly, the solubility of most 3D-SCCs in 
water or physiological media is generally low. The 
only example of fully water-soluble construct per se 
(i.e. without additional water-soluble functionalities 
anchored) is the family of ruthenium-based prisms 
obtained by face-directed self-assembly, which was 
exploited to encapsulate and solubilize hydrophobic 
guests [75, 110, 145, 146]. Regarding 
palladium(II)-based SCCs, the solubility of the final 
cages is often a real challenge, despite the multiple 
positive charges carried by the constituting metal 
ions. In rare examples where effort was put into 
varying the counter-ions and increasing the water 
solubility of the ligands by anchoring small 
water-soluble biomolecules, the final cages remained 
insoluble [147-149]. Instead, bioconjugation of 
[Pd2L4]4+ cages to targeting peptides made the 
systems well water soluble [131]. 
The study of the drug encapsulation and release 
properties in SCCs is a key step in the validation of 
these systems for drug delivery. Understanding the 
driving forces of the host-guest chemistry is also 
pivotal to the optimization of the cage scaffolds. 
Various factors are already known to play a role, 
including possible interactions of the guest molecule 
with the host cavity (e.g. H-bonding, van der Waals, 
coordination and electrostatic interactions) as well as 
energetically favorable solvent rearrangement during 
guest desolvation. Recently, the encapsulation of the 
anticancer drug cisplatin in selected [Pd2L4]4+ cages 
featuring 2,6-bis(pyridine-3-ylethynyl)pyridine 
ligands has been studied by NMR spectroscopy, and 
the obtained results show that if the solvent is of 
sufficient polarity, metallodrug encapsulation can 
easily occur in the hydrophobic cavity of the cage 
despite the absence of specific host-guest interactions 
[150]. Conversely, polar solvent molecules capable of 
forming hydrogen-bond networks (including water) 
are likely to prefer not to be encapsulated by 
hydrophobic cage cavities, and will not compete with 
the cisplatin molecules. This hypothesis is 
corroborated by previous studies on M4L6 
metallacages for which guest encapsulation in polar 
protic solvents, such as water, appears to be driven by 
initial desolvation of the guest with concomitant 
rearrangement of the hydrogen bond networks in 
solution, more than by host-guest interactions alone 
[151]. 
Another strategy to consider when designing a 
drug delivery system is the controlled guest release of 
the drug at the intended target site, namely the tumor 
tissue. SCCs offer several options to achieve such 
controlled release, including competitive guest uptake 
[111, 152], light induced structural conformation 
change [153, 154], and redox mediated structural 
conformation changes [155, 156]. Although there are 
currently few examples of release mechanisms for 
therapeutic guest molecules, it can be envisioned that 
the pioneering proof-of-concept studies on the 
reversible control over the guest encapsulation event 
[157], as well as guest release studies on anionic, 
cationic and neutral guest molecules, will also be 
applicable to therapeutic payloads. 
Finally, an intriguing aspect of SCCs is the 
possibility to design supramolecular tumor-targeted 
modalities that combine detection and treatment 
through the self-assembly of emissive, metal-based 
coordination complexes. In fact, most ligands used to 
form SCCs, especially by edge-directed self-assembly, 
are highly conjugated systems endowed with 
luminescence properties [158]. Moreover, additional 
modifications and functional groups including 
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luminescent tags have been reported [159, 160]. 
However, in most cases, upon cage formation and 
coordination of the ligands to the metal ions, the so 
called “heavy metal effect” dramatically induces loss 
of luminescence of the final SCC [117], with some 
exceptions [161]. Modulation of the ligands and 
insertion of non-aromatic linkers allowed in some 
cases the maintenance of the luminescent properties 
of the attached fluorophore [159], but further studies 
are necessary to develop the full potential of SCCs as 
imaging tools in cells and tissues.  
Certainly, the combination of SCCs with 
radioactive isotopes for diagnosis and therapy goes in 
this direction. Due to the huge combinatorial 
flexibility of SCC and SOCs towards the combination 
of ligands and metals, there are only few limitations of 
what the compounds in principle can be used for. The 
presented existing examples are limited to PET and 
MRI, but in the future also other techniques like X-ray 
CT might be interesting targets for SCC and SOC 
application. The SCC/SOCs could also combine 
existing tracers (like it was shown for technetates) and 
may enable orthogonal imaging using different 
techniques (e.g. guest for PET, host for MRI). 
Overall, the initial examples mentioned above 
show that supramolecular metal-based complexes 
could be used to create self-formulating drugs. In fact, 
the self-assembly of therapeutic agents into 
well-defined supramolecular nanostructures is an 
emerging concept in both fields of molecular 
assembly and drug delivery to obtain one-component 
nanomedicines of high reproducibility. 
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